Clinical Trial Update: A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN). [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating SPM 927 for postherpetic neuralgia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• SPM 927 (SPM 927)

Snippet

Sponsor: UCB Pharma | Conditions: Postherpetic Neuralgia | Phase 2 | Status: COMPLETED